Alpha Tau Medical (DRTS) Investor presentation summary

Technology and therapeutic approach

• Alpha DaRT uses localized alpha particle radiotherapy to precisely destroy solid tumors while sparing healthy tissue, leveraging the decay chain of Radium-224 for potent, short-range cytotoxic effects.

• Designed to overcome the limited range of alpha radiation by releasing alpha emitters into tumors, achieving tight, effective radiation distribution.

• Demonstrates potential for both local tumor control and systemic immuno-stimulatory activity, with broad applicability across multiple cancer types.

Clinical development and milestones

• Multiple clinical trials are underway for cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (HNSCC), pancreatic cancer, and glioblastoma (GBM).

• Key milestones include completion of pivotal and feasibility studies in the U.S. for cSCC, pancreatic cancer, and GBM by H2 2026, with potential FDA approval targeted for H1 2027.

• Supportive regulatory dialogue and expanding global manufacturing network underpin clinical and commercial progress.

Clinical results and patient outcomes

• In cSCC, Alpha DaRT showed a 100% complete response rate in a pilot study, with mild or moderate adverse events and no treatment-related serious AEs.

• Combination with pembrolizumab in HNSCC yielded a 75% systemic objective response rate and 37.5% complete response rate, with only mild Alpha DaRT-related adverse events.

• Interim pancreatic cancer trials reported a 19% objective response rate and 97% disease control rate (excluding feasibility patients), with ongoing survival analyses in key subgroups.

• In recurrent GBM, two of three patients achieved complete response and one had stable disease, with no local or distant recurrence and only one grade 3 SAE resolved with steroids.